Camp4 Therapeutics (CAMP) Net Income towards Common Stockholders (2023 - 2026)

Camp4 Therapeutics has reported Net Income towards Common Stockholders for 4 years, with the latest figure at -$12.2 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 10.49% year-over-year to -$12.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$56.1 million (up 8.65% YoY) and the FY2025 annual result came in at -$126.5 million, down 8.44% from the prior year.
• Net Income towards Common Stockholders eased to -$12.2 million in Q1 2026 per CAMP's latest filing, from -$9.7 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$9.7 million in Q4 2025 and troughed at -$23.8 million in Q3 2024.
• A 4-year average of -$14.2 million and a median of -$13.1 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders slumped 91.67% in 2024, then surged 40.68% in 2025.
• Over 4 years, Net Income towards Common Stockholders stood at -$13.0 million in 2023, then climbed by 15.83% to -$10.9 million in 2024, then rose by 11.55% to -$9.7 million in 2025, then fell by 26.33% to -$12.2 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$12.2 million, -$9.7 million, and -$14.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.